Fitzpatrick Tiffany, Perrier Laure, Tricco Andrea C, Straus Sharon E, Jüni Peter, Zwarenstein Merrick, Lix Lisa M, Smith Mark, Rosella Laura C, Henry David A
Ontario Strategy for Patient-Oriented Research (SPOR) SUPPORT Unit, Toronto, Ontario, Canada.
Gerstein Science Information Centre, University of Toronto Libraries, Toronto, Ontario, Canada.
BMJ Open. 2017 Feb 17;7(2):e013770. doi: 10.1136/bmjopen-2016-013770.
Well-conducted randomised controlled trials (RCTs) provide the least biased estimates of intervention effects. However, RCTs are costly and time-consuming to perform and long-term follow-up of participants may be hampered by lost contacts and financial constraints. Advances in computing and population-based registries have created new possibilities for increasing the value of RCTs by post-trial extension using linkage to routinely collected administrative/registry data in order to determine long-term interventional effects. There have been recent important examples, including 20+ years follow-up studies of trials of pravastatin and mammography. Despite the potential value of post-trial extension, there has been no systematic study of this literature. This scoping review aims to characterise published post-trial extension studies, assess their value, and identify any potential challenges associated with this approach.
This review will use the recommended methods for scoping reviews. We will search MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. A draft search strategy is included in this protocol. Review of titles and abstracts, full texts of potentially eligible studies and data/information extraction will be conducted independently by pairs of investigators. Eligible studies will be RCTs that investigated healthcare interventions that were extended by individual linkage to administrative/registry/electronic medical records data after the completion of the planned follow-up period. Information concerning the original trial, characteristics of the extension study, any clinical, policy or ethical implications and methodological or practical challenges will be collected using standardised forms.
As this study uses secondary data, and does not include person-level data, ethics approval is not required. We aim to disseminate these findings through journals and conferences targeting triallists and researchers involved in health data linkage. We aim to produce guidance for investigators on the conduct of post-trial extensions using routinely collected data.
精心设计的随机对照试验(RCT)对干预效果的估计偏差最小。然而,进行RCT成本高昂且耗时,参与者的长期随访可能会因失访和资金限制而受阻。计算机技术和基于人群的登记系统的进步为通过与常规收集的行政/登记数据进行关联的试验后扩展来增加RCT的价值创造了新的可能性,以便确定长期干预效果。最近有一些重要的例子,包括对普伐他汀试验和乳腺X线摄影试验的20多年随访研究。尽管试验后扩展具有潜在价值,但尚未对该文献进行系统研究。本综述旨在描述已发表的试验后扩展研究的特征,评估其价值,并识别与该方法相关的任何潜在挑战。
本综述将采用推荐的综述方法。我们将检索MEDLINE、EMBASE和Cochrane对照试验中央注册库。本方案中包含了一个初步的检索策略。标题和摘要的审查、潜在合格研究的全文以及数据/信息提取将由成对的研究人员独立进行。合格研究将是那些在计划的随访期结束后通过与行政/登记/电子病历数据的个体关联来扩展医疗保健干预研究的RCT。将使用标准化表格收集有关原始试验、扩展研究的特征、任何临床、政策或伦理影响以及方法或实际挑战的信息。
由于本研究使用的是二手数据,且不包括个人层面的数据,因此无需伦理批准。我们旨在通过针对试验人员和参与健康数据关联的研究人员的期刊和会议来传播这些研究结果。我们旨在为研究人员提供关于使用常规收集的数据进行试验后扩展的指导。